21 June 2024
Argent BioPharma Ltd.
(Argent BioPharma or the Company)
Appointment of UK Corporate Broker
Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, is pleased to announce the appointment of Shore Capital Stockbrokers Limited as the Company's UK Corporate Broker with immediate effect.
Roby Zomer, CEO & Managing Director of Argent BioPharma, commented:
"We are delighted to announce the appointment of Shore Capital as our new UK Corporate Broker. This is a further step in our comprehensive restructuring process to position Argent BioPharma in pioneering drug discovery within the biopharmaceutical sector, supported by the strengthening of our management team and advisory board. We look forward to working with the team at Shore Capital as we seek to enhance our visibility and engagement with investors."
-Ends-
Authorised for release by the board of directors, for further information please contact:
| Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950
| Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950 |
| UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 | UK Corporate Broker Shore Capital Toby Gibbs / James Thomas / Lucy Bowden +44 (0)207 408 4090 |
About Argent BioPharma
Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; ORCQB: RGTLF) is a Clinical-Stage, Revenue Generating Biopharmaceutical Company committed to providing accessible medical treatments for unmet medical needs, to bridge the gap where medical solutions currently fall short. The Group focuses on the Multidisciplinary method with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially relating to the Central nervous system ("CNS") and Immunology treatments.
About Shore Capital
Shore Capital is an independent securities business offering investment banking, research, sales and trading services to companies on both the Main Market and AIM.
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.